Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.755
/ Totale documenti scaricati: 30.918.264

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Slide background
Certifico 2000/2024: Informazione Utile




/ Documenti disponibili: 43.755 *

/ Totale documenti scaricati: 30.918.264 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile

/ Documenti disponibili: 43.755 *

/ Totale documenti scaricati: 30.918.264 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.755 *

/ Totale documenti scaricati: 30.918.264 *


Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.755 *

/ Totale documenti scaricati: 30.918.264 *

Vedi Abbonamenti Promo 2023

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

/ Documenti disponibili: 43.755 *

/ Totale documenti scaricati: 30.918.264 *


Vedi Abbonamenti Promo 2022

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.


Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2022
Slide background
Certifico 2000/2021: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021








Europe, Rome

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11

ID 15020 | | Visite: 1458 | NewsPermalink: https://www.certifico.com/id/15020

Temi: Coronavirus

EMA recommends approval for children aged 5 to 11

Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11

News 25/11/2021

EMA’s human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use in children aged 5 to 11. The vaccine, developed by BioNTech and Pfizer, is already approved for use in adults and children aged 12 and above.

In children from 5 to 11 years of age, the dose of Comirnaty will be lower than that used in people aged 12 and above (10 µg compared with 30 µg). As in the older age group, it is given as two injections in the muscles of the upper arm, three weeks apart.

A main study in children aged 5 to 11 showed that the immune response to Comirnaty given at a lower dose (10 µg) in this age group was comparable to that seen with the higher dose (30 µg) in 16- to 25-year-olds (as measured by the level of antibodies against SARS-CoV-2). The efficacy of Comirnaty was calculated in almost 2,000 children from 5 to 11 years of age who had no sign of previous infection. These children received either the vaccine or a placebo (a dummy injection). Of the 1,305 children receiving the vaccine, three developed COVID-19 compared with 16 out of the 663 children who received placebo. This means that, in this study, the vaccine was 90.7% effective at preventing symptomatic COVID-19 (although the true rate could be between 67.7% and 98.3%).

The most common side effects in children aged 5 to 11 are similar to those in people aged 12 and above. They include pain at the injection site, tiredness, headache, redness and swelling at the site of injection, muscle pain and chills. These effects are usually mild or moderate and improve within a few days of vaccination.

The CHMP therefore concluded that the benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19.

The safety and efficacy of the vaccine in both children and adults will continue to be monitored closely as it is used in vaccination campaigns in EU Member States through the EU pharmacovigilance system and ongoing and additional studies conducted by the company and by European authorities.

The CHMP will now send its recommendation to the European Commission, which will issue a final decision.

How Comirnaty works

Comirnaty works by preparing the body to defend itself against COVID-19. It contains a molecule called messenger RNA (mRNA) which has instructions for making the spike protein. This is a protein on the surface of the SARS-CoV-2 virus which the virus needs to enter the body’s cells.

When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike protein. The person’s immune system will then recognise this protein as foreign and produce antibodies and activate T cells (white blood cells) to attack it.

If, later on, the person comes into contact with the SARS-CoV-2 virus, their immune system will recognise it and be ready to defend the body against it.

The mRNA from the vaccine does not stay in the body but is broken down shortly after vaccination.

Where to find more information

The product information approved by the CHMP for Comirnaty contains prescribing information for healthcare professionals, a package leaflet for members of the public and details of conditions of the vaccine’s authorisation.

An assessment report, with details of EMA’s evaluation of use of Comirnaty in young children, will be published on the EMA website.

The studies in children were carried out in accordance with Comirnaty’s paediatric investigation plan (PIP), which was agreed by EMA's Paediatric Committee (PDCO). Clinical trial data submitted by the company in the application for the paediatric extension of indication will be published on the Agency’s clinical data website in due course.

More information is available in an overview of the vaccine in lay language, including a description of the vaccine’s benefits and risks and why EMA recommended its authorisation in the EU.

Monitoring the safety of Comirnaty

In line with the EU’s safety monitoring plan for COVID-19 vaccines, Comirnaty is closely monitored and subject to several activities that apply specifically to COVID-19 vaccines. Although large numbers of people have already received COVID-19 vaccines, certain side effects may still emerge as more and more people receive the vaccine.

BioNTech, the company that markets this vaccine in the EU, is required to provide regular updates and conduct studies to monitor the safety and effectiveness of the vaccine as it is used by the public. Authorities also conduct additional studies to monitor the vaccine.

These measures allow regulators to swiftly assess data emerging from a range of different sources and take appropriate regulatory action to protect public health if needed.

...

Fonte: EMA

Collegati

Tags: Coronavirus

Ultimi inseriti

EN 415 2 2025 Packaging machines for pre formed rigid containers
Lug 03, 2025 14

EN 415-2:2025 / Packaging machines for pre-formed rigid containers

EN 415-2:2025 / Packaging machines for pre-formed rigid containers ID 24216 | 03.07.2025 / Preview attached EN 415-2:2025Safety of packaging machines - Part 2: Packaging machines for pre-formed rigid containers Valid from 01.07.2025 This document applies to the following machines and to machines… Leggi tutto
UNI 11555 2025 Posatori di sistemi a secco in lastre
Lug 03, 2025 38

UNI 11555:2025 / Posatori di sistemi a secco in lastre

UNI 11555:2025 / Posatori di sistemi a secco in lastre ID 24215 | 03.07.2025 / In allegato Preview UNI 11555:2025Attività professionali non regolamentate - Posatori di sistemi a secco in lastre - Requisiti di conoscenza, abilità, autonomia e responsabilità La norma definisce i requisiti relativi al… Leggi tutto
Lug 02, 2025 230

Ordinanza Emilia-Romagna n. 150 del 30 giugno 2025

Ordinanza Emilia-Romagna n. 150 del 30 giugno 2025 / Rischio calore solare lavoro ID 24211 | 02.07.2025 Dal 2 luglio 2025 in Emilia-Romagna ferme le attività tra le ore 12.30 e le 16, nei cantieri edili e affini, in agricoltura, nel florovivaismo e nei piazzali della logistica, quando il livello di… Leggi tutto
Lug 02, 2025 563

Ordinanza Regione Veneto n. 34 del 01 luglio 2025

Ordinanza Regione Veneto n. 34 del 01 luglio 2025 / Rischio calore solare lavoro ID 24210 | 02.07.2025 Ordinanza del Presidente della Giunta regionale n. 34 del 01 luglio 2025 Disposizioni di carattere contingibile e urgente in merito all’attività lavorativa svolta nel settore agricolo e… Leggi tutto
Lug 02, 2025 148

Ordinanza Regione Emilia-Romagna n. 101 del 26 luglio 2024

Ordinanza Regione Emilia-Romagna n. 101 del 26 luglio 2024 / Rischio calore solare lavoro ID 24209 | 02.07.2025 Ordinanza contingibile e urgente per motivi di igiene e sanità pubblica - misure di prevenzione per attività lavorativa nel settore agricolo e florovivaistico nonché nei cantieri edili e… Leggi tutto
EN 17639 2025
Lug 02, 2025 105

EN 17639:2025

EN 17639:2025 / Cableway installations - General safety requirements ID 24207 | 02.07.2025 / Preview attached EN 17639:2025Safety of machinery - Cableway installations designed for the transport of material and specially designated persons - General safety requirements This Type C standard document… Leggi tutto

Ultimi Documenti Abbonati

EN 415 2 2025 Packaging machines for pre formed rigid containers
Lug 03, 2025 14

EN 415-2:2025 / Packaging machines for pre-formed rigid containers

EN 415-2:2025 / Packaging machines for pre-formed rigid containers ID 24216 | 03.07.2025 / Preview attached EN 415-2:2025Safety of packaging machines - Part 2: Packaging machines for pre-formed rigid containers Valid from 01.07.2025 This document applies to the following machines and to machines… Leggi tutto
UNI 11555 2025 Posatori di sistemi a secco in lastre
Lug 03, 2025 38

UNI 11555:2025 / Posatori di sistemi a secco in lastre

UNI 11555:2025 / Posatori di sistemi a secco in lastre ID 24215 | 03.07.2025 / In allegato Preview UNI 11555:2025Attività professionali non regolamentate - Posatori di sistemi a secco in lastre - Requisiti di conoscenza, abilità, autonomia e responsabilità La norma definisce i requisiti relativi al… Leggi tutto
EN 17639 2025
Lug 02, 2025 105

EN 17639:2025

EN 17639:2025 / Cableway installations - General safety requirements ID 24207 | 02.07.2025 / Preview attached EN 17639:2025Safety of machinery - Cableway installations designed for the transport of material and specially designated persons - General safety requirements This Type C standard document… Leggi tutto
Programma nazionale di esplorazione mineraria
Lug 01, 2025 219

Programma nazionale di esplorazione mineraria

Programma nazionale di esplorazione mineraria / Approvato 01.07.2025 ID 24201 | 01.07.2025 / In allegato Approvato il Programma nazionale di esplorazione mineraria La problematica della sicurezza nell’approvvigionamento delle risorse minerarie indispensabili per lo sviluppo industriale e la… Leggi tutto